Full-Time
Updated on 9/4/2026
Develops psilocybin-based therapies for TRD
$165k - $195k/yr
No H1B Sponsorship
Wichita, KS, USA + 1 more
More locations: Topeka, KS, USA
In Person
Field-based role requiring travel of up to 70%, depending on geography.
Bachelor's
See people who can refer or advise you
COMPASS Pathways develops psilocybin-based therapies for mental health, focusing on treating treatment-resistant depression (TRD). Its lead drug candidate, COMP360, is a high-purity psilocybin formulation given alongside psychological support from trained therapists. The treatment is delivered through a global Phase 3 program, aiming to establish a regulatory-approved therapy. Compared with other players, COMPASS emphasizes a standardized therapeutic model that pairs a pharmaceutical compound with guided psychotherapy and has the largest psilocybin Phase 3 program to date, supported by Breakthrough Therapy designation from the FDA. The company originated from a nonprofit idea, transformed into a for-profit entity to fund extensive trials, and is pursuing regulatory approval and eventual commercialization through licensing and partnerships. Its goal is to bring approved, evidence-based psilocybin treatments to patients with TRD and scale access through a commercial pathway.
Company Size
201-500
Company Stage
IPO
Headquarters
London, United Kingdom
Founded
2016
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Hybrid Work Options
Company Equity
Compass Pathways recognized as a 2026 Fierce 50 Breakthrough honoree. September 2, 2026 · Logan Lenz COMPASS Pathways Plc (CMPS) - LONDON & NEW YORK, September 02, 2026-Compass Pathways, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, has been named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech and Fierce Healthcare. The Fierce 50 recognizes 50 individuals and organizations driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare.
Compass Pathways shares rose over 6% on Monday, contributing to a 25% gain in August, as the company prepares to complete its FDA application for COMP360, a synthetic psilocybin treatment for treatment-resistant depression. The firm expects to finish the full submission in the fourth quarter of this year, with a potential launch in the first half of 2027 if approved. The FDA previously granted COMP360 a special priority voucher, which could reduce the final review period to just one or two months. In early August, Compass reported a cash position of $433 million as of June, sufficient to fund operations into 2028. Two large late-stage studies demonstrated COMP360's quick-acting, long-lasting benefits. The company is also advancing a late-stage PTSD study whilst building commercial capabilities.
Compass Pathways working with U.S. Department of veterans Affairs for investigational study of psilocybin. August 6, 2026 · Logan Lenz COMPASS Pathways Plc (CMPS) - LONDON & NEW YORK, August 06, 2026-Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumat
Compass Pathways to participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026. LONDON & NEW YORK-(BUSINESS WIRE)- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, and will participate in a fireside chat at 8:00am ET. Management will also participate in the Stifel Biotech Summit in Newport, Rhode Island, on August 10, 2026. A live audio webcast of this event will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways NovumPR believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Its initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. NovumPR is leading the world's largest classic psychedelic clinical program in TRD, and building upon that robust foundation, NovumPR is executing a late-stage trial evaluating COMP360 for PTSD, another condition with high unmet need. Its goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing. Compass is headquartered in London, UK, with a U.S. office in New Jersey. NovumPR is driven by its purpose of unlocking pathways to be - opening futures filled with possibility. Together, NovumPR is on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery, because every journey needs a Compass.
Compass Pathways announced second quarter and first half 2026 financial results as it progresses towards potential FDA approval of COMP360, its synthetic psilocybin treatment for treatment-resistant depression. The company reported cash and cash equivalents of $433.3 million as of 30 June 2026, up from $149.6 million at year-end 2025. Net loss was $162.6 million for the first half, compared with $56.3 million in the same period of 2025, primarily due to non-cash warrant fair value adjustments. Compass completed a rolling NDA submission to the FDA and expects to finalise remaining modules in Q4 2026. The company received a National Priority Voucher that could accelerate review time to one to two months. Commercial launch is expected in first half 2027, subject to FDA approval and DEA rescheduling. Current cash position is projected to fund operations into 2028.